You're very welcome. Scynexis seems like a company that is laser-focused on advancing their drug candidate. Hopefully, FDA will allow them to file under the LPAD pathway next year.

Back in December, SCXY shares fell to .36, valuing the company at about 23m, I think. Kind of crazy, since they had about 45m in cash and several Ph3 and Ph2 trials which have a high probability of success.